190 related articles for article (PubMed ID: 10839301)
1. Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.
Ramp U; Dejosez M; Mahotka C; Czarnotta B; Kalinski T; Wenzel M; Lorenz I; Müller M; Krammer P; Gabbert HE; Gerharz CD
Br J Cancer; 2000 Jun; 82(11):1851-9. PubMed ID: 10839301
[TBL] [Abstract][Full Text] [Related]
2. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control.
Gerharz CD; Ramp U; Déjosez M; Mahotka C; Czarnotta B; Bretschneider U; Lorenz I; Müller M; Krammer PH; Gabbert HE
Lab Invest; 1999 Dec; 79(12):1521-34. PubMed ID: 10616203
[TBL] [Abstract][Full Text] [Related]
3. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
Déjosez M; Ramp U; Mahotka C; Krieg A; Walczak H; Gabbert HE; Gerharz CD
Cell Death Differ; 2000 Nov; 7(11):1127-36. PubMed ID: 11139287
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.
Müller M; Strand S; Hug H; Heinemann EM; Walczak H; Hofmann WJ; Stremmel W; Krammer PH; Galle PR
J Clin Invest; 1997 Feb; 99(3):403-13. PubMed ID: 9022073
[TBL] [Abstract][Full Text] [Related]
6. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
[TBL] [Abstract][Full Text] [Related]
7. The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.
Toth C; Funke S; Nitsche V; Liverts A; Zlachevska V; Gasis M; Wiek C; Hanenberg H; Mahotka C; Schirmacher P; Heikaus S
Cell Commun Signal; 2017 May; 15(1):16. PubMed ID: 28464919
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
[TBL] [Abstract][Full Text] [Related]
9. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status.
Reinecke P; Kalinski T; Mahotka C; Schmitz M; Déjosez M; Gabbert HE; Gerharz CD
Cancer Lett; 2005 May; 222(2):165-71. PubMed ID: 15863265
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for the Fas-/Fas-Ligand pathway in chemoresistance of human squamous cell carcinomas of the head and neck (SCCHN)?
Sproll KC; Balló H; Hoffmann TK; Scheckenbach K; Koldovsky U; Balz V; Hafner D; Ramp U; Bier H
Oral Oncol; 2009 Jan; 45(1):69-84. PubMed ID: 18620901
[TBL] [Abstract][Full Text] [Related]
12. The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis.
Müller M; Scaffidi CA; Galle PR; Stremmel W; Krammer PH
Eur Cytokine Netw; 1998 Dec; 9(4):685-6. PubMed ID: 9889415
[TBL] [Abstract][Full Text] [Related]
13. Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas.
Heikaus S; Casliskan E; Mahotka C; Gabbert HE; Ramp U
Apoptosis; 2007 Sep; 12(9):1645-57. PubMed ID: 17610067
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of apoptosis induced by cytotoxic drugs.
Fulda S; Friesen C; Debatin KM
Klin Padiatr; 1998; 210(4):148-52. PubMed ID: 9743944
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells.
Scheltema JM; Romijn JC; van Steenbrugge GJ; Schröder FH; Mickisch GH
Anticancer Res; 2001; 21(5):3161-6. PubMed ID: 11848468
[TBL] [Abstract][Full Text] [Related]
16. Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma.
Zhou X; Tolstov Y; Arslan A; Roth W; Grüllich C; Pahernik S; Hohenfellner M; Duensing S
Neoplasia; 2014 Dec; 16(12):1028-35. PubMed ID: 25499216
[TBL] [Abstract][Full Text] [Related]
17. Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines.
van Geelen CM; de Vries EG; Le TK; van Weeghel RP; de Jong S
Br J Cancer; 2003 Jul; 89(2):363-73. PubMed ID: 12865931
[TBL] [Abstract][Full Text] [Related]
18. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression.
Mishima K; Nariai Y; Yoshimura Y
Int J Cancer; 2003 Jul; 105(5):593-600. PubMed ID: 12740905
[TBL] [Abstract][Full Text] [Related]
20. Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1(CD95)-mediated apoptosis in renal-cell-cancer cells.
Tomita Y; Kawasaki T; Bilim V; Takeda M; Takahashi K
Int J Cancer; 1996 Sep; 68(1):132-5. PubMed ID: 8895553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
